drugset / Trial / NCT00630760
Oral NRX 194204 in Patients With Refractory Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I study will determine the safety profile of NRX 194204 on this schedule; it will evaluate the pharmacokinetic profile of NRX 194204 in cancer patients; and will investigate anti-tumor activity as manifested by standard response criteria, or by tumor markers.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX4204 | Small molecule | 3 mg/m2 | Oral |